What was LUMOSA THERAPEUTICS CO LTD’s price range in the past 12 months?
LUMOSA THERAPEUTICS CO LTD lowest stock price was TWD 63.30 and its highest was TWD 222.00 in the past 12 months.
What is LUMOSA THERAPEUTICS CO LTD’s market cap?
LUMOSA THERAPEUTICS CO LTD’s market cap is TWD 11.78B.
When is LUMOSA THERAPEUTICS CO LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LUMOSA THERAPEUTICS CO LTD’s earnings last quarter?
LUMOSA THERAPEUTICS CO LTD released its earnings results on May 11, 2026. The company reported -TWD 0.721 earnings per share for the quarter, missing the consensus estimate of -TWD 0.72 by -TWD 0.001.
Is LUMOSA THERAPEUTICS CO LTD overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does LUMOSA THERAPEUTICS CO LTD pay dividends?
LUMOSA THERAPEUTICS CO LTD does not currently pay dividends.
What is LUMOSA THERAPEUTICS CO LTD’s EPS estimate?
LUMOSA THERAPEUTICS CO LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LUMOSA THERAPEUTICS CO LTD have?
LUMOSA THERAPEUTICS CO LTD has 167,840,820 shares outstanding.
What happened to LUMOSA THERAPEUTICS CO LTD’s price movement after its last earnings report?
LUMOSA THERAPEUTICS CO LTD reported an EPS of -TWD 0.721 in its last earnings report, missing expectations of -TWD 0.72. Following the earnings report the stock price went down -0.143%.
Which hedge fund is a major shareholder of LUMOSA THERAPEUTICS CO LTD?
Currently, no hedge funds are holding shares in TW:6535
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LUMOSA THERAPEUTICS CO LTD
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Sector
General
Industry
Biotechnology
CEO
Jung Chin Lin
Employees
36
Website
www.lumosa.com.tw
Address
No. 3-2, Park Street, Taipei, TPE, 11503, TW
LUMOSA THERAPEUTICS CO LTD (6535) Earnings & Revenues